Compare Amgen, Inc. (AMGN) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Alliant Energy Corporation — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Alliant Energy Corporation trades at $76.4 (market cap $19.73B). The key difference: Amgen, Inc. is far larger — about 9.9× Alliant Energy Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | LNT | |
|---|---|---|
Market Cap | $196.12B | $19.73B |
Sector | Health | Utilities |
52-Week High | $388.16 | $78.03 |
52-Week Low | $271.18 | $61.85 |
Enterprise Value | $241.41B | $31.45B |
Dividend Yield | 2.77% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
LNT trades at $76.40, up 0.92% today, with a bullish technical signal and mixed earnings history including a recent Q1 2026 beat. The company shows steady revenue growth to $4.36B in 2025 and a net margin of 18.58%, supported by a $13.4B investment plan and data center demand. Analysts are split with a 52% buy rating and a $75.67 consensus target, while the stock pays a $0.54 dividend.
Outlook is positive due to strategic investments and sector tailwinds, but risks include rising debt levels and interest rate sensitivity. The stock offers growth and income appeal, though investors should monitor execution on capital expenditures and competitive pressures in the utility space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
